Monographie - Foscarnet sodium - Stabilis 4.0

Last update :
19/11/2024

Antiviral

Foscarnet sodium

injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Chemical structure

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Foscarnet	Argentina, Chile, United States of America
Foscarvir	Japan
Foscavir	Australia, Austria, Belgium, France, Germany, Great Britain, Greece, Hungary, Italy, Luxembourg, Netherlands, New Zealand, Spain, Sweden, Switzerland, United States of America

References

injection

References : Foscarnet sodium

	Type	Publication
2	Journal	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	Journal	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	Journal	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	Journal	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	Journal	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	Journal	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	Journal	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Manufacturer	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Manufacturer	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Journal	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Manufacturer	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales